PharmaNet Development Group, the US-based contract research organisation that has been suffering from a flurry of project cancellations in its late-stage business, is expanding its immunochemistry, cell biology and bioanalytical laboratories at its subsidiary Taylor Technology.
Located in Princeton, New Jersey, Taylor is one of four PharmaNet subsidiaries offering bioanalytical laboratory services. The other three are Anapharm, Anapharm Europe and Keystone Analytical.
Taylor Technology specialises in bioanalytical mass spectrometry and immunochemistry, operating out of around 18,000 sq ft of laboratory space in Princeton. The expansion programme will create about 24,000 sq ft of extra space, “dramatically” enhancing PharmaNet’s capabilities in imunoassays, cell-based assays and protein chemistry for both biotechnology clients and trial sponsors developing vaccines and blood products, said Mark Di Ianni, president, early stage development.
“The new laboratory complements our well-established immunochemistry expertise already available in our laboratory in Canada [i.e., Anapharm],” Di Ianni added.
As well as biologics capabilities, a Thermo Scientific TSQ VantageT mass spectrometer is being added to the Princeton site. Moreover, PharmaNet plans to consolidate its Pennsylvania-based Keystone Analytical laboratories at Princeton during 2009.
